Opendata, web and dolomites

LEUKEYOLK SIGNED

Uncovering the origin and mechanisms of Down syndrome-associated leukaemia through human induced pluripotent stem cell-derived haemopoiesis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LEUKEYOLK project word cloud

Explore the words cloud of the LEUKEYOLK project. It provides you a very rough idea of what is the project "LEUKEYOLK" about.

dissecting    assays    paradigmatic    megakaryocytic    recapitulation    cell    first    definitive    lineages    yolk    independent    extensive    area    molecular    perinatal    haemopoietic    hscs    suggests    onset    hyperproliferation    functional    disease    hypothesis    contribution    mechanisms    megakaryoblast    vitro    haemopoiesis    transcriptional    embryonic    childhood    origin    myeloid    malignancies    ipsc    elucidated    ds    least    myeloproliferative    designing    generating    patient    competitiveness    interrogate    developmental    malignancy    leukaemogenesis    leukemias    rarely    progenitors    emp    erythromyeloid    leukaemias    broad    embryogenesis    primitive    beginning    therapies    hsc    landscape    ec    nurture    vivo    shift    derives    source    fp7    cells    pluripotent    differentiation    gata1    ipscs    devoid    compelling    hypothesise    appreciated    utero    disorder    waves    lastly    transient    shown    cancer    supports    mutations    stem    syndrome    tmd    isoform    differentiating    followed    patients    paradigm    life    ys    sac   

Project "LEUKEYOLK" data sheet

The following table provides information about the project.

Coordinator
OSPEDALE SAN RAFFAELE SRL 

Organization address
address: VIA OLGETTINA 60
city: MILANO
postcode: 20132
website: www.hsr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 168˙277 €
 EC max contribution 168˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OSPEDALE SAN RAFFAELE SRL IT (MILANO) coordinator 168˙277.00

Map

 Project objective

This project aims at dissecting the contribution of yolk sac (YS)-derived haemopoietic progenitors to childhood leukaemias, whose early onset suggests an embryonic origin. Using induced pluripotent stem cell (iPSC) differentiation, we will determine the origin of the Down syndrome-associated transient myeloproliferative disease (DS-TMD), paradigmatic example of perinatal malignancy. TMD, due to megakaryoblast hyperproliferation, has an in utero origin. This supports the compelling hypothesis of a haemopoietic stem cell (HSC)-independent origin of DS-TMD, as during embryogenesis there are at least 3 waves of progenitors with megakaryocytic potential. A first primitive program, followed by the erythromyeloid progenitors (EMP), both YS-derived and devoid of HSC potential; lastly a definitive program, generating HSCs and all haemopoietic lineages. By differentiating iPSCs from a DS-TMD patient through recapitulation of embryonic development, we will interrogate the contribution of primitive, EMP and definitive haemopoiesis to DS-TMD with in vitro/in vivo functional assays. Moreover, we will investigate the molecular mechanisms triggering the disease. As mutations leading to a short GATA1 isoform occur in all cases of DS-TMD, we will analyse how this affects the transcriptional landscape of the cells relevant to the disease. We hypothesise that DS-TMD derives from a rarely appreciated developmental program (the EMP), whose life-long contribution is only beginning to be elucidated. Determining the developmental source and mechanisms of this disorder could help designing new therapies for myeloid malignancies in non-DS patients and could lead to a paradigm shift in the field of haemopoiesis and leukaemogenesis. Research on cancer and childhood leukemias is of broad interest for the EC, as shown by the extensive funding of projects on this topic within the FP7. Our project will further nurture this research area, contributing to increasing European research competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKEYOLK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEUKEYOLK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MetEpiC (2020)

P53-dependent Metabolic and Epigenetic Reprogramming in Carcinogenesis

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More